343 related articles for article (PubMed ID: 16932428)
21. Long-term comparison of rituximab treatment for refractory systemic lupus erythematosus and vasculitis: Remission, relapse, and re-treatment.
Smith KG; Jones RB; Burns SM; Jayne DR
Arthritis Rheum; 2006 Sep; 54(9):2970-82. PubMed ID: 16947528
[TBL] [Abstract][Full Text] [Related]
22. Clinical effects and safety of rituximab for treatment of refractory pediatric autoimmune diseases.
El-Hallak M; Binstadt BA; Leichtner AM; Bennett CM; Neufeld EJ; Fuhlbrigge RC; Zurakowski D; Sundel RP
J Pediatr; 2007 Apr; 150(4):376-82. PubMed ID: 17382113
[TBL] [Abstract][Full Text] [Related]
23. B cell monitoring of transplant patients treated with anti-CD20.
Abdallah KO; Prak ET
Clin Transpl; 2006; ():427-37. PubMed ID: 18365400
[TBL] [Abstract][Full Text] [Related]
24. The therapeutic use of rituximab in non-Hodgkin's lymphoma.
Marcus R; Hagenbeek A
Eur J Haematol Suppl; 2007 Jan; (67):5-14. PubMed ID: 17206982
[TBL] [Abstract][Full Text] [Related]
25. B-cell surface marker analysis for improvement of rituximab prophylaxis in ABO-incompatible adult living donor liver transplantation.
Egawa H; Ohmori K; Haga H; Tsuji H; Yurugi K; Miyagawa-Hayashino A; Oike F; Fukuda A; Yoshizawa J; Takada Y; Tanaka K; Maekawa T; Ozawa K; Uemoto S
Liver Transpl; 2007 Apr; 13(4):579-88. PubMed ID: 17394164
[TBL] [Abstract][Full Text] [Related]
26. Rituximab: a promising therapy in systemic lupus erythematosus.
Thatayatikom A; White AJ
Autoimmun Rev; 2006 Jan; 5(1):18-24. PubMed ID: 16338207
[TBL] [Abstract][Full Text] [Related]
27. B cells move to centre stage: novel opportunities for autoimmune disease treatment.
Browning JL
Nat Rev Drug Discov; 2006 Jul; 5(7):564-76. PubMed ID: 16816838
[TBL] [Abstract][Full Text] [Related]
28. Update on the role of rituximab in kidney diseases and transplant.
Ramanath V; Nistala R; Chaudhary K
Expert Opin Biol Ther; 2012 Feb; 12(2):223-33. PubMed ID: 22188359
[TBL] [Abstract][Full Text] [Related]
29. Rituximab removes intrarenal B cell clusters in patients with renal vascular allograft rejection.
Steinmetz OM; Lange-Hüsken F; Turner JE; Vernauer A; Helmchen U; Stahl RA; Thaiss F; Panzer U
Transplantation; 2007 Oct; 84(7):842-50. PubMed ID: 17984836
[TBL] [Abstract][Full Text] [Related]
30. Failure of anti-CD20 monoclonal antibody therapy to prevent antibody-mediated rejection in three crossmatch-positive renal transplant recipients.
Matignon M; Tagnaouti M; Audard V; Dahan K; Lang P; Grimbert P
Transplant Proc; 2007 Oct; 39(8):2565-7. PubMed ID: 17954175
[TBL] [Abstract][Full Text] [Related]
31. A review of rituximab in cutaneous medicine.
Scheinfeld N
Dermatol Online J; 2006 Jan; 12(1):3. PubMed ID: 16638371
[TBL] [Abstract][Full Text] [Related]
32. Rituximab-induced B cell depletion in autoimmune diseases: potential effects on T cells.
Liossis SN; Sfikakis PP
Clin Immunol; 2008 Jun; 127(3):280-5. PubMed ID: 18337174
[TBL] [Abstract][Full Text] [Related]
33. B cells as therapeutic targets in autoimmune neurological disorders.
Dalakas MC
Nat Clin Pract Neurol; 2008 Oct; 4(10):557-67. PubMed ID: 18813230
[TBL] [Abstract][Full Text] [Related]
34. ABO blood type incompatible kidney transplantation without splenectomy prepared with plasma exchange and rituximab.
Chikaraishi T; Sasaki H; Tsutsumi H; Miyano S; Nakazawa R; Nakano T; Kitajima K; Kudo H; Takahashi T; Sato Y; Kimura K
Transplant Proc; 2008 Dec; 40(10):3445-7. PubMed ID: 19100409
[TBL] [Abstract][Full Text] [Related]
35. Impaired B-cell reconstitution in lymphoma patients undergoing allogeneic HSCT: an effect of pretreatment with rituximab?
Buser A; Stern M; Arber C; Medinger M; Halter J; Rovo A; Favre G; Lohri A; Tichelli A; Gratwohl A
Bone Marrow Transplant; 2008 Oct; 42(7):483-7. PubMed ID: 18695668
[TBL] [Abstract][Full Text] [Related]
36. The therapeutic potential of anti-CD20 "what do B-cells do?".
Eisenberg R; Looney RJ
Clin Immunol; 2005 Dec; 117(3):207-13. PubMed ID: 16169773
[TBL] [Abstract][Full Text] [Related]
37. Rituximab for humoral rejection after kidney transplantation: an update.
Rostaing L; Guilbeau-Frugier C; Kamar N
Transplantation; 2009 Apr; 87(8):1261. PubMed ID: 19384176
[No Abstract] [Full Text] [Related]
38. Treatment of vascular rejection with rituximab in cardiac transplantation.
Garrett HE; Duvall-Seaman D; Helsley B; Groshart K
J Heart Lung Transplant; 2005 Sep; 24(9):1337-42. PubMed ID: 16143254
[TBL] [Abstract][Full Text] [Related]
39. ABO-incompatible kidney transplantation and rituximab.
Tydén G; Kumlien G; Genberg H; Sandberg J; Lundgren T; Fehrman I
Transplant Proc; 2005 Oct; 37(8):3286-7. PubMed ID: 16298574
[TBL] [Abstract][Full Text] [Related]
40. NK cell-mediated lysis is essential to kill Epstein-Barr virus transformed lymphoblastoid B cells when using rituximab.
Markasz L; Vanherberghen B; Flaberg E; Otvös R; Stuber G; Gustafsson Jernberg A; Olah E; Skribek H; Szekely L
Biomed Pharmacother; 2009 Jul; 63(6):413-20. PubMed ID: 18834693
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
